Back to search results

A Study of BMS-986490 for Advanced Solid Tumors

This study is looking at a new treatment called BMS-986490, both by itself and in combination with another medicine called Bevacizumab. It's for people with advanced solid tumors that have spread and can't be removed, and are known to have a specific marker called CEACAM5. The main goal is to see how safe these treatments are by tracking any side effects, including serious ones, and those that might limit the dose. The study aims to enroll about 360 participants. To join, you must be at least 18 years old and have a confirmed advanced solid tumor. For colorectal cancer (CRC) specifically, your disease must have progressed after other treatments.

Study design
This study is for about 360 participants with advanced solid tumors. It is testing BMS-986490 alone and with Bevacizumab.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for side effects for up to 100 days after they stop taking the study medicine.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06730750

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~360 participants
Updated 2026-09-01 on ClinicalTrials.gov
What's tested:BMS-986490Bevacizumab

At a glance

Recruiting sites
0 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participnats with Adverse Events (AEs)
Measured over Up to 100 days following discontinuation of dosing
+4 more outcomes measured

Conditions

Advanced Solid Tumors

Explore related trials

Colorectal CarcinomaGastric CarcinomaLung Non-Small Cell CarcinomaSolid Neoplasm

NCT06730750

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Local Institution - 0003

    Toronto, Ontario, Canadano site contact published

  • Local Institution - 0004

    Hackensack, New Jerseyno site contact published

  • Local Institution - 0006

    Pittsburgh, Pennsylvaniano site contact published

  • Local Institution - 0007

    Los Angeles, Californiano site contact published

  • Local Institution - 0017

    Grand Rapids, Michiganno site contact published

  • Tasman Oncology Research

    Southport, Queensland, Australiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:
NSCLC: Part 2A-NSCLC/GC, 2L+ NSCLC:

Exclusion

History of anaphylactic reactions to irinotecan and/or bevacizumab.
Previously received therapy targeting CEACAM5.
Grade ≥3 ILD/pneumonitis.

What this trial measures

  • Number of participnats with Adverse Events (AEs)Up to 100 days following discontinuation of dosing
  • Number of participants with Serious AEs (SAEs)Up to 100 days following discontinuation of dosing
  • Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteriaUp to 28 days after the first treatment of study intervention
  • Number of participants with AEs leading to discontinuationUp to 100 days following discontinuation of dosing
  • Number of deathsUp to 100 days following discontinuation of dosing